Trial Profile

Electrophysiological Biomarkers of Kynurenine Pathway Modulator AV-101 in Healthy Volunteers: Treating Suicidal Veterans

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 11 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AV 101 (Primary)
Indications Major depressive disorder; Neuropathic pain; Psychiatric disorders; Suicidal ideation
Focus Biomarker; Therapeutic Use

19 Dec 2019 According to a VistaGen Therapeutics media release, VistaGen and the U.S. Department of Veterans Affairs (VA) entered into a Material Transfer Cooperative Research and Development Agreement (MT CRADA) regarding clinical trial material for this study, and VA funding was provided for all other study costs.
19 Dec 2019 According to a VistaGen Therapeutics media release, Michael E. DeBakey VA Medical Center (MEDVAMC) in Houston served as Principal Investigator of the study.
19 Dec 2019 Results presented in a VistaGen Therapeutics Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com